1.63

1.55% 0.02

After Hours: 1.64 0.01 +0.61%

Coherus Oncology Inc (CHRS)

Overview News Price History Option Chain Financials Why CHRS Down? Discussions Forecast

Coherus Oncology Inc stock is traded at $1.63, with a volume of 1.17M. It is up +1.55% in the last 24 hours and down -6.57% over the past month. Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.

Previous Close:

$1.61

Open:

$1.65

24h Volume:

1.17M

Relative Volume:

0.92

Market Cap:

$251.43M

Revenue:

$42.17M

Net Income/Loss:

$-183.12M

P/E Ratio:

-1.1194

EPS:

-1.4562

Net Cash Flow:

$-138.51M

1W Performance:

+10.47%

1M Performance:

-6.57%

6M Performance:

+24.81%

1Y Performance:

+116.24%

1-Day Range:

$1.63

$1.715

1-Week Range:

$1.47

$1.715

52-Week Range:

$0.71

$2.6158

Coherus Oncology Inc Stock (CHRS) Company Profile

Name

Coherus Oncology Inc

Sector

Healthcare (1113)

Industry

Biotechnology (618)

Phone

(650) 649-3530

Address

C/O DENNIS M. LANFEAR, REDWOOD CITY, CA

Employee

145

Twitter

@coherus_bio

Next Earnings Date

2026-05-11

Latest SEC Filings

CHRS's Discussions on Twitter

Compare CHRS vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CHRS Coherus Oncology Inc	1.63	248.34M	42.17M	-183.12M	-138.51M	-1.4562
VRTX Vertex Pharmaceuticals Inc	435.92	110.28B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	634.42	66.98B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	808.61	50.15B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	295.50	39.71B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	154.89	32.22B	742.00K	-1.37B	-1.07B	-7.0731

Coherus Oncology Inc Stock (CHRS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-23-26	Initiated	Oppenheimer	Outperform
Sep-04-25	Upgrade	Maxim Group	Hold → Buy
Aug-16-24	Downgrade	UBS	Buy → Neutral
Nov-17-23	Initiated	Robert W. Baird	Outperform
Nov-08-23	Downgrade	Maxim Group	Buy → Hold
Jul-24-23	Initiated	Citigroup	Buy
May-01-23	Initiated	Truist	Buy
Mar-28-23	Upgrade	UBS	Neutral → Buy
Jun-14-22	Initiated	UBS	Neutral
Mar-07-22	Downgrade	JP Morgan	Overweight → Neutral
Jul-16-20	Initiated	BofA Securities	Neutral
Apr-17-20	Initiated	SunTrust	Buy
Aug-13-19	Initiated	Mizuho	Buy
Aug-02-19	Reiterated	H.C. Wainwright	Buy
Aug-02-19	Reiterated	Maxim Group	Buy
Jun-11-19	Initiated	Barclays	Overweight
May-07-19	Initiated	H.C. Wainwright	Buy
Aug-28-18	Initiated	H.C. Wainwright	Buy
Mar-09-18	Reiterated	Maxim Group	Buy
Aug-08-17	Reiterated	JP Morgan	Overweight
Jun-13-17	Reiterated	Maxim Group	Buy
May-05-17	Initiated	BMO Capital Markets	Outperform
Oct-19-16	Initiated	Robert W. Baird	Outperform
Sep-07-16	Initiated	Maxim Group	Buy
Jul-27-16	Initiated	Citigroup	Buy
Jan-20-16	Initiated	Credit Suisse	Outperform

View All

Coherus Oncology Inc Stock (CHRS) Latest News

May 22, 2026

CHRS Should I Buy - Intellectia AI

May 22, 2026

May 20, 2026

Coherus BioSciences stock (US19247A1007): short interest remains elevated as investors watch oncolog - AD HOC NEWS

May 20, 2026

Coherus Oncology Q1 earnings call highlights - MSN

May 20, 2026

What Does The Future Hold For Coherus Oncology, Inc. (NASDAQ:CHRS)? These Analysts Have Been Cutting Their Estimates - 富途牛牛

May 20, 2026

May 19, 2026

CHRS News | COHERUS ONCOLOGY INC (NASDAQ:CHRS) - ChartMill

May 19, 2026

May 18, 2026

Earnings call transcript: Coherus BioSciences Q1 2026 revenue miss prompts cautious outlook By Investing.com - Investing.com Australia

May 18, 2026

Earnings call transcript: Coherus BioSciences Q1 2026 revenue miss prompts cautious outlook - Investing.com UK

May 18, 2026

May 15, 2026

Timothy Youngquist Trust amends 13G; holds 12.75M CHRS (NASDAQ: CHRS) - Stock Titan

May 15, 2026

Coherus Oncology (CHRS) price target increased by 13.33% to 5.78 - MSN

May 15, 2026

May 14, 2026

Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase - ChartMill

May 14, 2026

What You Need To Know About The Coherus Oncology, Inc. (NASDAQ:CHRS) Analyst Downgrade Today - Yahoo Finance

May 14, 2026

Coherus Oncology (CHRS) Q1 Loss Of US$36.9 Million Tests Bullish Growth Narratives - Sahm

May 14, 2026

May 13, 2026

Maxim Group Maintains Coherus Oncology(CHRS.US) With Buy Rating, Maintains Target Price $4 - Moomoo

May 13, 2026

Coherus Oncology, Inc. (NASDAQ:CHRS) Q1 2026 Earnings Call Transcript - Insider Monkey

May 13, 2026

Coherus Oncology: Setting Up For Important Readouts In Mid-2026 (NASDAQ:CHRS) - Seeking Alpha

May 13, 2026

Coherus targets $15M quarterly LOQTORZI sales in 2026 while advancing midyear tagmokitug and casdozokitug readouts - MSN

May 12, 2026

Coherus Oncology, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance

May 12, 2026

H.C. Wainwright Maintains Coherus Oncology(CHRS.US) With Buy Rating, Maintains Target Price $7 - Moomoo

May 12, 2026